Latigo Biotherapeutics (NASDAQ:LTGO) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Latigo Biotherapeutics (NASDAQ:LTGO) from a hold rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

LTGO has been the subject of a number of other research reports. Jefferies Financial Group initiated coverage on Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $50.00 price objective for the company. Guggenheim assumed coverage on Latigo Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $50.00 target price for the company. The Goldman Sachs Group initiated coverage on Latigo Biotherapeutics in a research report on Tuesday. They issued a “buy” rating and a $73.00 price target for the company. Finally, Leerink Partners began coverage on Latigo Biotherapeutics in a research note on Tuesday. They issued an “outperform” rating and a $36.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Latigo Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Trading Up 2.5%

NASDAQ:LTGO opened at $23.04 on Friday. Latigo Biotherapeutics has a twelve month low of $17.22 and a twelve month high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO) last released its earnings results on Thursday, September 3rd. The company reported ($27.59) EPS for the quarter.

Insider Activity

In other Latigo Biotherapeutics news, Director James B. Tananbaum bought 140,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the purchase, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of the stock in a transaction on Monday, August 10th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.